Healthcare provider profile · identity verified

Judy Hsu, MD

Internal Medicine · SAN FRANCISCO, CA · NPI 1043384050

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	779	180
Atorvastatin Calcium	Atorvastatin Calcium	601	164
Valsartan	Valsartan	402	100
Metoprolol Succinate	Metoprolol Succinate	351	92
Omeprazole	Omeprazole	242	93
Irbesartan	Irbesartan	223	61
Famotidine	Famotidine	211	91
Gabapentin	Gabapentin	206	76
Metformin Hcl	Metformin Hcl	197	53
Losartan Potassium	Losartan Potassium	193	55
Triamcinolone Acetonide	Triamcinolone Acetonide	167	85
Alendronate Sodium	Alendronate Sodium	134	44
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	134	76
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	126	126
Tamsulosin Hcl	Tamsulosin Hcl	126	40
Jardiance	Empagliflozin	121	38
Fluticasone Propionate	Fluticasone Propionate	118	56
Atenolol	Atenolol	114	30
Escitalopram Oxalate	Escitalopram Oxalate	111	40
Rosuvastatin Calcium	Rosuvastatin Calcium	104	30
Glipizide	Glipizide	101	26
Terazosin Hcl	Terazosin Hcl	101	30
Simvastatin	Simvastatin	100	28
Hydrochlorothiazide	Hydrochlorothiazide	97	31
Metformin Hcl Er	Metformin Hcl	94	28
Diclofenac Sodium	Diclofenac Sodium	93	61
Levothyroxine Sodium	Levothyroxine Sodium	92	24
Finasteride	Finasteride	89	27
Januvia	Sitagliptin Phosphate	88	27
Pantoprazole Sodium	Pantoprazole Sodium	78	27
Allopurinol	Allopurinol	74	23
Chlorhexidine Gluconate	Chlorhexidine Gluconate	74	22
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	69	35
Mirtazapine	Mirtazapine	67	24
Lisinopril	Lisinopril	54	16
Ventolin Hfa	Albuterol Sulfate	52	26
Metoprolol Tartrate	Metoprolol Tartrate	51	14
Furosemide	Furosemide	49	14
Eliquis	Apixaban	47	18
Glipizide Er	Glipizide	44	16
Fluocinonide	Fluocinonide	40	19
Ketoconazole	Ketoconazole	39	20
Meloxicam	Meloxicam	38	23
Zolpidem Tartrate	Zolpidem Tartrate	38	21
Montelukast Sodium	Montelukast Sodium	37	11
Telmisartan	Telmisartan	36	15
Meclizine Hcl	Meclizine Hcl	35	16
Xarelto	Rivaroxaban	34	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	12
Hydralazine Hcl	Hydralazine Hcl	33	suppressed
Procto-Med Hc	Hydrocortisone	33	16
Vemlidy	Tenofovir Alafenamide	33	suppressed
Trazodone Hcl	Trazodone Hcl	30	16
Lidocaine	Lidocaine	29	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	26	18
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	26	26
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	26	suppressed
Nitroglycerin	Nitroglycerin	26	14
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Acarbose	Acarbose	24	suppressed
Rifampin	Rifampin	23	14
Dicyclomine Hcl	Dicyclomine Hcl	22	11
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	20	20
Benazepril Hcl	Benazepril Hcl	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Prednisone	Prednisone	18	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Raloxifene Hcl	Raloxifene Hcl	17	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Hydrocortisone	Hydrocortisone	16	12
Potassium Chloride	Potassium Chloride	16	suppressed
Colchicine	Colchicine	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Loperamide	Loperamide Hcl	15	11
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Methimazole	Methimazole	13	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	13	12
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Ciclopirox	Ciclopirox Olamine	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error